For decades, type 2 diabetes has been understood as a story of two organs failing in parallel — a liver that overproduces glucose and a pancreas that cannot keep pace with insulin. Researchers at Kyoto University have now identified a single protein, CA8, that appears to govern both processes through a shared molecular mechanism, suggesting the disease may be less a coincidence of separate failures than a coordinated system unraveling from within. The finding does not yet reach the clinic, but it quietly reframes the question: rather than asking how to fix each organ, medicine may need to ask
Protein CA8 emerges as dual-organ regulator for type 2 diabetes treatment
A single brake in two organs producing opposite outcomes
Mark
So this protein CA8 acts as a brake in both the liver and pancreas, but the brakes work in opposite directions?
Mimi
Exactly. In a healthy person, CA8 restrains glucose production in the liver and restrains insulin secretion in the pancreas. But in type 2 diabetes, the expression pattern flips—it goes up in the pancreas and down in the liver, which is the opposite of what you'd want.
Luke
How confident are we that this is actually what's happening in human diabetes, though? These are mouse experiments.
Mimi
That's the honest limitation. The researchers tested the mechanism in isolated mouse tissues and genetically modified mice. They didn't work with human pancreatic or liver cells.
Mark
But they did find elevated CA8 in mice fed high-fat diets, which mimics obesity-related diabetes in humans?
Mimi
Yes, and they looked at public genetic data from those studies. The pattern held up. But that's still observational—correlation, not proof of causation in humans.
Luke
Right. And the glucagon desensitizing effect they described—that's interesting, but it's also based on mouse pancreatic tissue in a dish, not a living human body.
Mimi
True. The researchers are explicit about this. They say further human tissue studies are necessary before CA8 becomes a therapeutic target.
Mark
So what's the real value of this work right now?
Mimi
It's conceptual. It shows that type 2 diabetes might not be two separate organ problems but one shared molecular system expressing differently in each tissue. That changes how you think about treatment.
Luke
And if that's true, it could mean a single drug targeting CA8 might work on both organs at once, rather than needing separate therapies for the liver and pancreas.
Mimi
Exactly. But we won't know if that works until someone tests it in humans.
El Pulso
- A single protein called CA8 has been found to act as a brake on both liver glucose production and pancreatic insulin secretion — a discovery that challenges the assumption that type 2 diabetes is simply two organs failing independently.
- In diabetic and obese mice, CA8 expression flips in a pattern that mirrors the disease itself — rising in the pancreas while falling in the liver — creating the very imbalance that defines type 2 diabetes.
- When researchers restored CA8 function specifically in the liver of affected mice, excess fasting glucose dropped, offering a proof-of-concept that targeting this single regulator could correct multi-organ dysfunction.
- The protein may also explain why glucagon-based therapies show promise: chronic glucagon exposure elevates CA8, which then dampens further glucagon response — a desensitizing loop CA8 appears to mediate.
- The findings remain in the mouse model stage, and human tissue validation is the critical next step before CA8 can be considered a viable therapeutic target.
For decades, type 2 diabetes has been understood as a story of two organs failing in parallel — a liver that overproduces glucose and a pancreas that cannot keep pace with insulin. Researchers at Kyoto University have now identified a single protein, CA8, that appears to govern both processes through a shared molecular mechanism, suggesting the disease may be less a coincidence of separate failures than a coordinated system unraveling from within. The finding does not yet reach the clinic, but it quietly reframes the question: rather than asking how to fix each organ, medicine may need to ask what holds them together.
Type 2 diabetes is defined by a familiar imbalance: the liver releases too much glucose while the pancreas produces too little insulin to contain it. Kyoto University researchers have now identified a protein — carbonic anhydrase VIII, or CA8 — that appears to regulate both sides of this equation, raising the possibility that what looks like two organ failures may be one shared mechanism breaking down in two places at once.
Led by Muhammad Fauzi and Takaaki Murakami, the team studied mice engineered to lack functional CA8, measuring insulin secretion, glucose production, and calcium signaling across pancreatic and liver tissue. Their central finding was paradoxical: CA8 acts as a brake in both organs, yet its absence produces opposite effects in each. Without CA8, the liver overproduces glucose and the pancreas oversecrets insulin. In diabetic mice, the pattern reverses — CA8 rises in the pancreas and falls in the liver, a mirror image of the disease state itself. Restoring CA8 expression in the liver alone was enough to reduce excess glucose production and lower blood glucose levels.
The team also found that chronic exposure to glucagon — the hormone that drives glucose production — elevated CA8 in pancreatic tissue, which then blunted the tissue's sensitivity to further glucagon stimulation. This loop may help explain why glucagon-based therapies have shown promise in diabetes treatment. Analysis of public genetic data from high-fat-diet mice further linked elevated pancreatic CA8 to obesity-driven metabolic stress.
Fauzi described the conceptual weight of the finding: a single intracellular regulator producing tissue-specific outcomes in two organs, reframing diabetes as a coordinated system gone wrong rather than isolated dysfunction. Murakami argued that treatment strategies should begin treating the pancreas and liver as a unified glucose-control system. The research remains preliminary — mouse physiology does not always translate to humans — but the shift in perspective it offers may prove as significant as any molecule it names.
Type 2 diabetes emerges from a fundamental imbalance: the liver pumps out too much glucose while the pancreas fails to release enough insulin to control it. Researchers at Kyoto University have identified a single protein that appears to regulate both processes, suggesting that what looks like two separate organ failures may actually stem from dysfunction in a shared molecular system.
The protein is called carbonic anhydrase VIII, or CA8. It binds to a calcium-release channel in cells and has been observed in both pancreatic tissue and liver cells, yet its role in metabolism remained unclear. The team, led by Muhammad Fauzi and Takaaki Murakami, set out to test whether CA8 might coordinate glucose control across these two organs by studying mice genetically engineered to lack functional CA8. They measured insulin secretion, glucose production, calcium signaling, and gene expression in isolated pancreatic islets and liver cells, then used pharmacological tests to confirm their findings.
What they discovered was striking: CA8 acts as a brake on both organs, but in opposite directions. When CA8 is absent, the liver produces more glucose and the pancreas releases more insulin. In obese and diabetic mice, however, the pattern inverts—CA8 expression rises in the pancreas while falling in the liver, a reversal that mirrors the disease itself: insufficient insulin and excessive glucose production. The researchers also found that when they restored CA8 expression specifically in the liver, it reduced the excess glucose production that occurs during fasting and lowered blood glucose levels.
One finding hints at how this mechanism might explain why certain diabetes treatments work. When the researchers exposed pancreatic tissue to glucagon—the hormone that triggers glucose production—chronic exposure increased CA8 expression, which then dampened the tissue's response to further glucagon stimulation. This desensitizing effect, mediated by CA8, may explain why glucagon-based therapies show promise in type 2 diabetes treatment. The team also analyzed public genetic data from mice fed high-fat diets and found elevated CA8 expression in pancreatic islets, suggesting the protein plays a role in how obesity contributes to diabetes.
Fauzi noted the conceptual significance: a single intracellular regulator functioning as a common brake in two organs yet producing opposite physiological outcomes in each. This tissue-specific duality reframes type 2 diabetes not as two independent failures but as a coordinated system gone wrong. Murakami emphasized that the findings suggest treatment strategies should view the pancreas and liver as a unified glucose-control system rather than targeting each organ separately.
The work remains preliminary. The experiments were conducted in mice, and the physiology of rodent metabolism does not always translate directly to humans. The researchers acknowledge that human tissue studies and cellular work are necessary before CA8 can move from laboratory finding to clinical therapy. But the conceptual shift—understanding type 2 diabetes as a multi-organ disease rooted in tissue-specific changes to a shared molecular mechanism—may reshape how researchers approach treatment development. The next phase will test whether this dual-organ perspective holds in human biology.
Citas Notables
A single intracellular regulator could act as a common brake in two organs but produce very different physiological outcomes— Muhammad Fauzi, first author
This multi-organ disease can arise from tissue-specific changes in a shared molecular mechanism— Takaaki Murakami, corresponding author
Quieres la nota completa?
Lee el original en News-Medical ↗
Health & Medicine